Women With Pigmentary Maculopathy That Took Elmiron Should File Eye Damage Lawsuits Over Failure To Warn

Doctors today continue to sell Elmiron like nothing was the matter

Thursday, December 30, 2021 - Thousands of women are diagnosed with interstitial cystitis (IC) every day and prescribed Elmiron (pentosan polysulfate sodium) by their urologist to help alleviate their painful bladder syndrome and the desire to urinate twenty or more times per day. Most women with IC also report that having sexual relations is painful. Elmiron must build up in the blood and be taken for three to six months before any pain relief can be expected. Doctors prescribe Elmiron despite the warnings that are now prominently displayed on the drug's website OrthoElmiron.com. Janssen Pharmaceuticals and Johnson & Johnson enjoyed a monopoly for almost two decades as the only drug company to sell Elmiron. Elmiron (PPS) was approved by the FDA in 1996. Physicians that prescribe Elmiron are doing a disservice to their patients that would do better by following the IC dietary advice given by the Interstitial Cystitis Network. IC sufferers may also wish to try acupuncture and Super Aloe Vera Capsules. All three IC therapies including avoiding certain bladder-irritating acids could do all that it takes to get urinary issues under control. Doctors instead are trained to take the easy, profitable, way out and just prescribe Elmiron and ignore the Elmiron eye problems. The main injury being caused by Elmiron is a condition called pigmentary maculopathy, changes in the pigment of the back of the eye called the retina. Elmiron patients are warned that pigmentary maculopathy will continue to worsen even if one stops taking Elmiron. The website warns: "Tell your healthcare provider including your eye doctor right away if you have any vision changes including any of these symptoms: difficulty reading, your vision takes longer to adjust to low or reduced light, blurred vision." Elmiron users also report other serious side effects like bruising easily, nosebleeds, bleeding gums, and blood in the stool... all indications to stop taking Elmiron. The website also warns readers about side effects that almost every Elmiron patient suffers. "hair loss, diarrhea, nausea, stomach pain, upset stomach, headache, rash, abnormal liver function tests, and dizziness."

About 700 women to date that have suffered night blindness from taking Elmiron have filed Elmiron eye lawsuits seeking to hold Janssen Pharmaceuticals and Johnson & Johnson accountable for failing to warn them of the dangers of taking the drug. The number of lawsuits is expected to quietly double in 2022. The scientific evidence linking Elmiron with eyesight damage is strong and will be presented to juries at bellwether trials in 2023. It is expected that a settlement offer will be on the table at some point after hearing the jury's reaction to the evidence. Elmiron costs patients about $600 per month and yields about $150 million in sales to Janssen and Johnson & Johnson annually. The makers of Elmiron are being accused in Elmiron eye lawsuits of failing to test the drug before offering it to the public. According to AboutLawsuits.com, "The complaint filed earlier this month by Gloria Granberg and her husband, Mike, in New Jersey federal court, pursuing claims against Janssen Pharmaceuticals, Ortho-McNeil Pharmaceuticals, Inc., Alza Corporation, and Johnson & Johnson for failing to warn about the risk of eye injury and the need for medical monitoring while taking the medication."

More Recent Elmiron Eye Lawsuit News:

Lawyers for Elmiron Eye Lawsuits

Attorneys handling Elmiron Eye lawsuits for leukemia, non-Hodgkin lymphoma, and multiple myeloma offer free, no-obligation case review for individuals and families who believe they may have grounds to file a Elmiron Eye lawsuit. Working on a contingency basis, these attorneys are committed to never charging legal fees unless they win compensation in your Elmiron Eye lawsuit. The product liability litigators handling Roundup claims at OnderLaw have a strong track record of success in representing families harmed by dangerous drugs and consumer products.